The debate over healthcare costs is nothing new. But like many topics where every-day Americans find themselves at the intersection of policy and economic matters, the COVID-19 pandemic has only further heightened the impact of a critical drug pricing rule finalized by the Centers for Medicare and Medicaid Services (CMS) in the closing days of 2020.
